Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HiPSC-CAR-T
- Development stage
- Preclinical
- Lead developer
- Healios
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HiPSC-CAR-T is an investigational allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy derived from human induced pluripotent stem cells (iPSCs). Developed by Healios, this therapy utilizes the company's proprietary Universal Donor iPSC (UDC) platform, which employs genomic editing to reduce the risk of immune rejection, potentially allowing for administration to a broad patient population without the need for patient-specific manufacturing. The CAR-T cells are engineered to recognize and eliminate tumor cells expressing specific antigens associated with solid malignancies. The program is currently in preclinical development for the treatment of various solid tumors, including mesothelioma, lung cancer, hepatocellular carcinoma, and gastric cancer.
- Other names
- human induced pluripotent stem cell-derived chimeric antigen receptor T cellsiPSC-derived CAR-T cell therapyUDC-CAR-T
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HiPSC-CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HiPSC-CAR-T.